Incyte Corporation Earnings Conference Call (Q2 2012) Today's Calls 
Visit the TF Network Sites
Visit the TF Network Sites
· Corporate IR Center
· Institutional Investor Center
· Individual Investor Center
Download Plug-In
Real Player 8 Basic
Windows Media Player
Other Conference Calls
Other Aug 2 Calls
Today's Calls
Call Details
Incyte Corporation Earnings Conference Call (Q2 2012)
Scheduled to start Thu, Aug 2, 2012, 8:30 am Eastern

-- this event is ongoing now--
Listen to the ongoing live event audio stream

About Incyte Corp (NasdaqGS:INCY)Other Calls 
Incyte Corporation focuses on the discovery and development of proprietary small molecule drugs for hematologic and oncology indications, and for chronic inflammatory and autoimmune diseases. Its product pipe line includes INCB18424, which is in Phase III clinical trial for myelofibrosis; Phase II trial for polycythemia vera/essential thrombocythemia; Phase I/II trial to treat other hematologic tumors; and Phase IIb trail for the treatment of psoriasis. The company’s portfolio also includes INCB28050, a Phase II clinical trial product for rheumatoid arthritis; INCB28060, a Phase I product for solid cancers; INCB7839, a Phase II product for breast cancer; INCB24360, an IND cleared product for oncology; and INCB13739, a Phase IIb product to treat type 2 diabetes. It has a collaborative research and license agreements with Pfizer Inc.; Novartis International Pharmaceutical Ltd.; and Eli Lilly and Company. The company was founded in 1991 and is headquartered in Wilmington, Delaware.


More Info: Quote | Chart | News | Profile | Reports | Research | SEC | Msgs | Insider | Financials | Analyst Ratings


Copyright © 2012 Yahoo! Inc. All Rights Reserved. Privacy Policy - Terms of Service
Copyright © 2012 FirstCall Events. Historical chart data provided by Commodity Systems, Inc. (CSI). Company profile information presented on this page is Copyright Capital IQ. Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers (such as Capital IQ, CSI, etc.) shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon.